Rhizome AI recently launched!

Launch YC: Rhizome AI - Know what the FDA thinks

"Instantly answer regulatory questions with up to 1,000 documents from public health authority databases without hallucinations."
TL;DR What has the FDA’s feedback been on real world evidence in review comments? Rhizome AI helps life science companies know what the FDA thinks.

Regulatory affairs teams ask a question and get an answer backed by terabytes of regulatory & clinical databases from the US, EU, etc.

Unlike ChatGPT, Rhizome reads up to 1,000 documents per question, accompanies each statement with a citation, and doesn’t hallucinate.

Founded by Chetan Mishra

Hi everyone, meet Chetan, the founder of Rhizome AI.

Ask: If you know any biotech or medtech leaders (esp. if they’re regulatory affairs or R&D), Chetan would appreciate an intro!

Ultimately Chetan wants all reg affairs teams to be as informed as the most regulatory man in the world.

🤝 Who The Founder Is

A bit about Chetan's background. He joined EvolutionaryScale as their first product engineer, launching an AI inference platform to help scientists design proteins. He joined Instabase as #16 helping banks with document & imaging processing, closing $7m as the technical lead. When looking to start his own company, Chetan realized there are many AI startups focused on drug discovery, but a lot less attention bringing those products to market.

😖 The Problem: Knowing What The FDA Thinks

The FDA is the customer of every function in life sciences. It doesn’t matter whether you are regulatory affairs, R&D, quality, manufacturing, commercial, etc.

At the same time, it’s difficult to understand their thinking. Guidance documents are high level and vague. The only alternative is doing (or paying a consultant to do) manual, painful research on past decisions they’ve made and understand why. Other regulators around the globe are no easier.

ChatGPT / Claude / etc. have only made it worse:

  • They trust their knowledge and only look up what they feel the need to. This means low-latency, but high-hallucination research.
  • Even when they retrieve sources, at most, it’s a few dozen. It’s also liable to include lots of internet junk mixed in with the authoritative government databases the industry trusts.
  • They don’t make it easy to check citations. They cite a 1200 page PDF and you don’t really know where to dig inside it.

✨ The Solution: Hallucination-Free, Deep Research For Life Sciences

Rhizome solves this problem by providing hallucination-free and thorough deep research for the life sciences. There’s a few key things their customers like:

  • Rhizome didn’t have a single hallucination reported in 2025.
  • Every statement comes with a citation.
  • Rhizome reads up to 1,000 documents per question in a few minutes before writing an answer. They’re continuously extending this limit.

Here’s a quick peek at the product:

Animated GIF

Rhizome customers love it. A few testimonials:

  • “Last time we did this research, we spent weeks. Rhizome found the answer immediately.” - a VP of reg affairs at a clinical-stage biotech.
  • “Chetan idk what kind of magic you all did here, it’s so good.” - a VP of reg affairs at a biotech with multiple products on the market.
  • “I would cry if I lost access to Rhizome.” - an RA manager at a drug delivery device company.
  • “10 minutes of work can accomplish what would have taken weeks.”- a device engineer at a pharma company.

Learn More

🌐 Visit rhizomeai.com to learn more.
🙏 The Ask: Connections with regulatory affairs, quality, or R&D leaders in life sciences.
🤝 Do you know any regulatory affairs, quality, or R&D leaders in life sciences? It would be awesome to chat with them!

📣 Share this post with your friends / family in life sciences!

👣 Follow Rhizome AI on LinkedIn.

Posted 
January 30, 2026
 in 
Launch
 category
← Back to all posts  

Join Our Newsletter and Get the Latest
Posts to Your Inbox

No spam ever. Read our Privacy Policy
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.